Relapse after complete response to anthracycline-based combination chemotherapy in metastatic breast cancer

Breast Cancer Research and Treatment

Volumn 55, Issue 1, 1999, Pages 1-8

  Pusztai, Lajos ^a   Asmar, Lina ^a   Smith, Terry L ^a   Hortobagyi, Gabriel N ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Breast cancer relapse; Complete response (CR); Metastatic breast cancer; Survival after CR

Indexed keywords

ALKYLATING AGENT; ANTHRACYCLINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; METHOTREXATE;

ADULT; ARTICLE; BREAST CANCER; BREAST METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL FEATURE; DISEASE COURSE; DRUG RESISTANCE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RELAPSE; VISCERA;

ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; SURVIVAL ANALYSIS; SURVIVORS;

EID: 0032867023     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006161906667     Document Type: Article

References (23)

1. 1. Hortobagyi GN: Multidisciplinary management of advanced primary and metastatic breast cancer. Cancer 74: 416-423, 1994
2. 2. Greenberg PAC, Hortobagyi GN, Smith TL, et al. Long term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol 14: 2197-2205, 1996
3. 3. Goldie JH: Drug resistance. In: Perry MC (ed) The Chemotherapy Source Book. Williams & Wilkins, Baltimore, 1996, pp 63-69
4. 4. Morrow CS, Cowan K: Drug resistance and its clinical circumvention. In: Holland JF, Bast RC, Morton DL, et al.: (eds) Cancer Medicine. Williams & Wilkins, Baltimore, 1997, pp 799-815
5. 5. Kuukasjarvj T, Karhu R, Tanner M, et al.: Genetic heterogeneity and clonal evolution underlying development of asynchronous metastasis in human breast cancer. Cancer Res 57: 1597-1604, 1998
6. 6. Pusztai L, Hortobagyi GN: High dose chemotherapy: How resistant is breast cancer? Drug Resist Updates 1: 62-72, 1998
7. 7. Hayward JL, Carbone PP, Heuson JC, et al.: Assessment of response to therapy in advanced breast cancer. Cancer 39: 1289-1294, 1977
8. 8. Demicheli R, Abbattista A, Miceli R, et al.: Time distribution of the recurrence risk for breast cancer patients undergoing mastectomy: Further support about the concept of tumor dormancy. Breast Cancer Res Treat 41: 177-185, 1996
9. 9. Retsky MW, Demicheli R, Swartzendruber DE, et al.: Computer simulation of a breast cancer metastasis model. Breast Cancer Res Treat 42: 193-202, 1997
10. 10. Bloom HJG, Richardson WW, Harries EJ, et al.: Natural history of untreated breast cancer (1805-1933): Comparison of untreated and treated cases according to histological grade of malignancy. Br J Med 28: 213-221, 1962
11. 11. Henderson IC, Canellos GP: Cancer of the breast: The past decade. N Engl J Med 302: 17-30, 1980
12. 12. Tormey DC, Gelman R, Band PR, et al.: Comparison of induction chemotherapies for metastatic breast cancer. Cancer 50: 1235-1244, 1982
13. 13. Falkson G, Gelman RS, Pandya KJ, et al.: Eastern Cooperative Oncology Group randomized trials of observation versus maintenance therapy for patients with metastatic breast cancer in complete remission following induction treatment. J Clin Oncol 16: 1669-1676, 1998
14. 14. Ayash LJ, Wheeler C, Fairclough D, et al.: Prognostic factors for prolonged progression-free survival with high-dose chemotherapy with autologous stem-cell support for advanced breast cancer. J Clin Oncol 13: 2043-2049, 1995
15. 15. Tomiak E, Piccart M, Mignolet F, et al.: Characterization of complete responders to combination chemotherapy for advanced breast cancer: A retrospective EORTC breast group study. Eur J Cancer 32A: 1876-1887, 1996
16. 16. Fischer J, Rose CJ, Rubens RD: Duration of complete response to chemotherapy in advanced breast cancer. Eur J Cancer Clin Oncol 18: 747-757, 1982
17. 17. Legha SS, Buzdar A, Smith TL, et al.: Complete remission in metastatic breast cancer treated with combination drug therapy. Ann Int Med 91: 847-852, 1979
18. 18. Hietanen P, Miettanen M, Makinen J: Survival after first recurrence in breast cancer. Eur J Cancer Clin Oncol 22: 913-919, 1986
19. 19. Goldhirsch A, Gelber RD, Castiglione M, et al.: Relapse of breast cancer after adjuvant treatment in premenopausal and perimenopausal women: Patterns and prognosis. J Clin Oncol 6: 89-97, 1988
20. 20. Hortobagyi GN, Smith TL, Legha SS, et al.: Multivariate analysis of prognostic factors in metastatic breast cancer. J Clin Oncol 1: 776-786, 1983
21. 21. Clark GM, Sledge GW, Osborne CK, et al.: Survival from first recurrence: Relative importance of prognostic factors in 1,015 breast cancer patients. J Clin Oncol 5: 55-61, 1987
22. 22. Pivot X, Asmar L, Hortobagyi GN, et al.: A unified definition of clinical anthracycline-resistant breast cancer. Proc Am Soc Clin Oncol 16: 512, 1997
23. 23. Falkson G, Gelman R, Glick J, et al.: Reinduction with the same cytostatic treatment in patients with metastatic breast cancer: An Eastern Cooperative Oncology Group study. J Clin Oncol 12: 45-49, 1994